Table 2. Metastasis-free survival (MFS) and overall survival (OS) of 620 lymph node-negative patients with ER+ primary breast tumours.

	MFS						OS
	Univariate			Multivariate			Univariate			Multivariate
	HR	95% CI	P-value	HR	95% CI	P-value	HR	95% CI	P-value	HR	95% CI	P-value
Age (years)			0.005			0.066			NS			NS
⩽40	1			1			1			1
41–55	0.76	0.50–1.14		0.81	0.53–1.24		0.88	0.55–1.41		0.92	0.57–1.50
56–70	0.54	0.35–0.83		0.45	0.24–0.87		0.80	0.49–1.30		0.61	0.3–1.26
>70	0.48	0.29–0.78		0.39	0.19–0.78		1.20	0.73–1.97		0.95	0.45–2.00
Menopausal status			0.013			NS			NS		NS
Pre	1			1			1			1
Post	0.71	0.54–0.93		1.08	0.64–1.81		1.12	0.84–1.50		1.24	0.7–2.20
Tumour size			0.074			NS			NS			NS
⩽2 cm	1			1			1			1
>2 cm	1.28	0.98–1.67		1.26	0.95–1.66		1.24	0.93–1.64		1.14	0.85–1.53
Grade			0.002			0.002			0.069			NS
Poor	1			1			1			1
Unknown	1.03	0.77–1.38		1.13	0.83–1.52		1.01	0.74–1.39		1.03	0.74–1.42
Moderate/good	0.53	0.35–0.79		0.55	0.36–0.83		0.65	0.44–0.98		0.70	0.47–1.06
ESR1 mRNA level
Continuous	0.96	0.91–1.02	NS	1.06	0.99–1.13	NS	0.99	0.93–1.05	NS	1.03	0.96–1.11	NS
PGR mRNA level
Continuous	0.91	0.85–0.97	0.003	0.90	0.84–0.96	0.002	0.89	0.83–0.95	0.001	0.88	0.81–0.94	<0.001
Factors analysed				Additions to the base modela						Additions to the base modela
NCOR2
Continuous	0.63	0.50–0.78	<0.001	0.67	0.54–0.83	<0.001	0.75	0.60–0.95	0.016	0.78	0.62–0.98	0.032
Median	0.62	0.47–0.82	0.001	0.68	0.51–0.89	0.006	0.73	0.55–0.97		0.031	0.78–0.58	1.04
CITED2
Continuous	0.69	0.58–0.84	<0.001	0.77	0.63–0.93	0.008	0.90	0.74–1.09	NS	0.90	0.73–1.11	NS
Median	0.62	0.47–0.82	0.001	0.71	0.53–0.94	0.017	0.73	0.55–0.97	0.028	0.75	0.55–1.01	0.054

Abbreviations: CI=confidence interval; HR=hazard ratio; NS=P-value >0.10.

^aFactors were separately introduced to the base multivariate model that included the factors age, menopausal status, tumour size, grade, ESR1 and PGR mRNA levels.